Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TENCON vs PHRENILIN FORTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tencon is a combination product containing butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA activity at GABA-A receptors, producing sedation and anxiolysis. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception. Caffeine is a non-selective adenosine receptor antagonist, promoting alertness and vasoconstriction.
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
Tension headache,Migraine headache (off-label)
Tension-type headache
5 mg orally once daily, increased to 10 mg if needed after 2 weeks; maximum 20 mg daily.
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
Terminal half-life 2-4 hours; prolonged to 6-15 hours in renal impairment (Cr Cl <30 m L/min).
Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease.
Butalbital is metabolized primarily by cytochrome P450 (CYP) enzymes. Acetaminophen is metabolized mainly in the liver via glucuronidation, sulfation, and oxidation (CYP2E1, CYP1A2, CYP3A4) to reactive metabolites that are conjugated with glutathione. Caffeine is metabolized by CYP1A2.
Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2.
Primarily renal excretion (66-74% unchanged); biliary/fecal excretion (26-34%).
Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally.
25-30% bound to albumin.
Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin.
0.3-0.5 L/kg; indicates distribution into total body water.
Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg.
Oral: 85-90% (extensive first-pass metabolism reduces bioavailability to 60-70% for parent drug, but active metabolite contributes).
Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete).
GFR >30 m L/min: no adjustment; GFR 15-30 m L/min: 5 mg once daily; GFR <15 m L/min: contraindicated.
Not formally established. Acetaminophen component: avoid in severe renal impairment (Cr Cl <10 m L/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for Cr Cl 10-50 m L/min.
Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity.
0.1 mg/kg orally once daily, maximum 5 mg; titrate after 2 weeks; maximum 10 mg.
Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred.
Initiate at 2.5 mg orally once daily; increase cautiously to maximum 10 mg daily.
Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
Hepatotoxicity with acetaminophen overdose; risk of dependence and withdrawal with butalbital (barbiturate); may impair ability to drive or operate machinery; avoid concurrent use with other acetaminophen-containing products; caution in patients with liver disease, renal impairment, or history of substance abuse.
Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment.
Known hypersensitivity to barbiturates, acetaminophen, or caffeine; porphyria; severe hepatic impairment; acute or chronic pain in patients with active alcoholism; concomitant use with other CNS depressants (relative contraindication).
Hypersensitivity to any component; porphyria; severe hepatic impairment; concomitant MAO inhibitor use (or within 14 days)
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and additive central nervous system depression. Limit caffeine-containing foods and beverages (coffee, tea, cola, chocolate) to avoid excessive stimulant effects and potential caffeine toxicity.
Avoid alcohol and caffeine-containing foods/drinks (e.g., coffee, tea, cola, chocolate) as they may increase side effects like jitteriness or insomnia. Grapefruit juice may alter caffeine metabolism; consider avoiding. No significant food interactions with acetaminophen or butalbital.
FDA Pregnancy Category B. No evidence of risk in first trimester based on animal studies; insufficient human data for second and third trimesters. Recommend use only if clearly needed.
First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk.
Unknown if excreted in human milk. M/P ratio not determined. Use with caution in nursing mothers.
Acetaminophen: minimal excretion, M/P ratio ~0.9, considered compatible. Butalbital: excreted in breast milk, M/P ratio ~0.6, may cause infant drowsiness or withdrawal; caution advised. Caffeine: M/P ratio ~0.5-0.8, generally safe in moderate amounts.
No dose adjustment recommended for pregnancy; increased renal clearance in late pregnancy may require dose titration based on therapeutic drug monitoring.
Increased renal clearance and volume of distribution in pregnancy may reduce acetaminophen and caffeine levels; no standard dose adjustment recommended. Butalbital: increased clearance due to hepatic enzyme induction and increased Vd; monitor for reduced efficacy; adjust dose based on clinical response. Avoid supratherapeutic doses.
Tencon is a combination analgesic containing acetaminophen, butalbital, and caffeine. It is indicated for tension headaches. Butalbital is a barbiturate with abuse potential; limit duration of use to avoid dependence. Acetaminophen hepatotoxicity risk increases with doses >4 g/day or in patients with hepatic impairment. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of barbiturate withdrawal (anxiety, tremor, seizures) if discontinued abruptly after prolonged use.
Phrenilin Forte is a combination of butalbital, acetaminophen, and caffeine used for tension-type headaches. Butalbital is a barbiturate with high abuse potential; limit to short-term use. Acetaminophen hepatotoxicity risk increases with chronic alcohol use. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of dependence or withdrawal. Avoid in patients with porphyria or severe hepatic impairment.
Take exactly as prescribed; do not exceed recommended dose.,Avoid alcohol while taking this medication due to increased liver damage risk.,Do not take with other products containing acetaminophen (e.g., Tylenol, cold medicines).,This drug can be habit-forming; do not use longer than directed.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Limit caffeine intake from other sources (coffee, tea, soda) to prevent overstimulation.,If you miss a dose, take it as soon as you remember; do not double the next dose.,Store at room temperature away from moisture and heat.
Take only as prescribed; do not exceed recommended dose due to risk of liver damage from acetaminophen.,Avoid alcohol while taking this medication to prevent liver toxicity.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Do not use with other products containing acetaminophen to avoid overdose.,If you have a history of substance abuse, inform your doctor; this drug can be habit-forming.,Notify your doctor if you experience signs of liver problems (e.g., yellowing of skin/eyes, dark urine) or symptoms of withdrawal (e.g., anxiety, insomnia, tremors).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TENCON vs PHRENILIN FORTE, answered by our medical review team.
TENCON is a Barbiturate combination analgesic that works by Tencon is a combination product containing butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA activity at GABA-A receptors, producing sedation and anxiolysis. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception. Caffeine is a non-selective adenosine receptor antagonist, promoting alertness and vasoconstriction.. PHRENILIN FORTE is a Barbiturate Combination Analgesic that works by Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TENCON and PHRENILIN FORTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TENCON is: 5 mg orally once daily, increased to 10 mg if needed after 2 weeks; maximum 20 mg daily.. The standard adult dose of PHRENILIN FORTE is: 1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TENCON and PHRENILIN FORTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TENCON is classified as Category C. FDA Pregnancy Category B. No evidence of risk in first trimester based on animal studies; insufficient human data for second and third trimesters. Recommend use only if clearly nee. PHRENILIN FORTE is classified as Category C. First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.